- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
Annouce the change of the spokesperson.
Annouce the change of the general manager.
Oneness announces the information about the investor's conference of 2021 Q4.
The Singapore Health Science Authority has accepted the NDA application of the diabetic foot ulcer new drug, Fespixon
Oneness Biotech Co., LTD. receives "Prior Authorisation for Import of Traditional Medicines" from Macau on Fespixon cream (Research code: ON101)
The partial efficacy data for the Phase 2a study of FB825 in the treatment of atopic dermatitis in the U.S. have been analyzed
The mechanism of action and Phase 3 MRCT results of the diabetic foot ulcer new drug, Fespixon have been accepted for an oral presentation at IDF Congress 2021
Oneness Biotech Co., Ltd. receives a Taiwan patent O titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" O on Fespixon cream (Research code: ON101).
News-Press Release of The Publication the Ph3 Data And The Mechanism of Action of Fespixon（ON101）on JAMA Network Open
Oneness Biotech and Tanner Pharma Group initiate early access program for Fespixon®, a novel macrophage-regulating new therapy for the treatment of diabetic foot ulcers
News-Diabetes Self-Management:New Cream Cures Foot Ulcers
Oneness Biotech Co., LTD. receives a Mexican patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
An Australian patent on the producing of recombinant glycoproteins with modified glycosylation was granted.
A Malaysian patent on the Anti-CεMx (FB825) antibody was granted.
Oneness has been notified by the US FDA on the acceptance of ON101 medical device 510(k) application